Member Info for Saxondale

Merry Christmas all , hope everyone had a nice break , and wishing you all a Happy New Year too .

News just breaking from LLS about another of their supported therapies getting FDA approval .

Friends in high places ;-)

LLS support contributed directly to this approval, with grants and scholar awards to several researchers working on this important immunotherapy.

https://www.lls.org/news/fda-approves-first-class-bispecific-antibody-treatment-follicular-lymphoma?utm_source=Twitter&utm_medium=Social&utm_campaign=12-27-2022-FDA-Approval-Bispecific-Antibody-Treatment-Follicular-Lymphoma-ZGM

Great news ! . Must admit I was starting to think it may never come .
This should get 2023 off to a flying start .
Merry Christmas all .

Can someone tell me that this is not massive news ?
Only 13% of CPI treatments are currently responsive .
Bex aims to increase that number significantly , by igniting the immune system .
Not only that , but after a short treatment with Bex , they can tell what CPI you are likely or not likely to respond to ( if treated with Bex in combination )

Essentially a fine tuning diagnostic tool that can be deployed to eliminate pointless CPI treatments when the patient would never respond , and selecting one that does .

Round peg in a round hole .

We hear of these developments way after they are actually made . Makes you wonder what else they know that is yet to be revealed .

These patents just keep rolling in .

If you can take the time to read the paragraphs below , it explains that with this discovery , they now have another biomarker for Bex that actually selects what combi treatment the patient is best suited to !!

No wonder the Bexcombo trial has been offered first line patients .

It just keeps getting better !

Now we have -
ANTI-CLEVER-1 AGENTS FOR CONTROLLING THE EXPRESSION OF CELL SURFACE MARKERS ON LEUCOCYTES, AND USING THESE TO GUIDE ANTI-CLEVER-1 BASED CANCER TREATMENT.

The present invention relates to monitoring expression levels of one or more cell surface marker in circulating T cell populations in relation to anti-Clever-1 treatment and choosing the best combination agent to initiate treatment together with anti-Clever-1 therapy after the observed changes in the expression of one or more cell surface marker.

By monitoring the change in these commonly known checkpoint molecules during anti-Clever-1 treatment, we can pick a checkpoint inhibitor that should be given in combination with the on-going anti-Clever-1 treatment. If a certain checkpoint molecule does not react to anti-Clever-1 treatment in the wanted way, then a specific checkpoint inhibitor targeting the wanted checkpoint molecule is administered in combination with to the on-going anti-Clever-1 treatment. The expression of cell surface markers can be used to guide anti-Clever-1 treatment or the best possible checkpoint inhibitor(s) combination treatment with anti-Clever-1 therapy.

he present invention also provides a novel biomarker-based combination treatment for cancer patients and thus reduce or even eliminate the abovementioned problems in defining non-responders from responding patients. The present invention gives the possibility of probing the molecular landscape of solid tumors via a blood draw to define changes in the patient during anti-Clever-1 therapy and subsequently gives the opportunity to select the best possible check-point inhibition combination treatment with anti-Clever-1 therapy.

https://patents.justia.com/patent/20220404366

sorry LLS , not LSS .
Had a couple of sherbets lol

I think we may look back next year and see the pivotal moment for Faron was when they gained the support of the LLS .

Not only did it raise the profile of Bexmab , but it allowed Faron a seat on the train that gets you to market if you have success .

Having a great trial result is one thing , but if you are not connected to the right mechanism to convert that into a commercial product , you are still in limbo .

Take this tweet today from LSS -
https://twitter.com/LLSusa/status/1605937993424027651?s=20&t=LwY_m0kRHIfrnHy5OEabiQ

They are actively seeking donations and support themselves , but justify their position as they are the most credible party out there who can seek out , support and finance new treatments to the point of approval .

In the last 5 years - 3 out of 4 of every blood cancers treatments approved by the FDA were supported by the LSS .

Only got a small holding here , but I just doubled it .

Merry Christmas all , see what comes in the next week or so .

I guess it's to keep the story out there for those that have yet to discover Faron ( which is 99.9% of the world by my reckoning )
Big Pharma have their own intel I'm sure , but it helps to lay the progress out there for non scientific analysts to look at .

I appreciate that in the past when he was pressed on the issue of finance , he brushed it off with ' we have options ' , and then the IPF Partners funding appeared , along with further placings , but I really think that we have arrived at a point where there really are 'proper' options , ie Partners .

We now have the Bexmab P1 data showing a potential breakthrough therapy ( on top of the all the other Bex data )

Every bit of news takes us closer to being a marketable therapy .

We now appear to be on the panel of the worlds most prestigious Leukemia research organisations latest podcast , following the publication of that Bexmab patient data .

I think we have the ear of the big players , and being still 100% wholly owned , will surely be in the position of having propositions put infront of us .

Bristol Myers Squibb , being a co partner of LSS , must surely have first movers advantage here , as they are closer than any of the other majors , and it would be a feather in their cap , along with LSS , to have their names associated with another product brought to market in the Hematology world , their latest big investment area .

But then we have the Matins pivotal trial plans , along with other combi trials planned .
A lot of funding options .

Faron needs partners , but then these majors need future drugs.

It just takes one arm of Bex to get cashflow , and we are up and away .

Or following the Matins P2 determination , someone decides they better move and have the lot .

Either way , I just have to trust that the BOD are up to the job. And in my opinion , with the investment the Jalkanens have involved , both financially , and in career and reputation , along with Toni , MLF , and all the team that has been built up in the last year or so , we have never been in a better position to make that next step up to being a revenue generating company.

Hear from LLS TAP staff and TAP European biotech partners who are dreaming big and making bold progress for blood cancer patients. 
https://www.youtube.com/watch?v=u9mu95uZapU&t=2s

Of course we are already part of the TAP program .
https://www.lls.org/therapy-acceleration-program-portfolio

Great to see Faron being part of this .
The next key player to get further funding ?

New event in the new year -
MLF on the panel for discussion
https://twitter.com/FaronPharm/status/1605600209655910401?s=20&t=MJg3V2GY7jQRA7Ux12KYtA
https://na.eventscloud.com/website/49472/welcome/

This TAP looks interesting -
https://na.eventscloud.com/website/49472/about-tap/

Predictable slippage after such a rise , but its a shame Faron can't keep its gains .
Like you say Laplom , the longer the void of news , the more suspicion there may be a placing .
Even if there is , I think this time , it will have a cherry and some icing on , as they are too far down the partnership discussion road to just dilute the company for a few more months of dosing and so forth .

I must be the exception to the rule today . Finally got my dividend , and plumped it straight back into UJO with pleasure , along with a couple of grand more .

Lets say the news is what we expect ( groundbreaking)
They've been working on this for years .
If they release news before Christmas - they will firstly be bombarded with requests for interviews / journals / investors.
Early Jan gives them all quality time with family etc to have a break , because next year is going to be super busy I think .

Sensible planning - and with the added meat on the bone Science Day to really answer all the questions .

You wouldn't get everyone together on a special day to tell them that it rubbish ?

Hope you're doing well CB . We've seen it all here from those days . Lets hope 2023 is our year . I wonder if Oilman is still about or holding here . Be nice for everyone who was here in the early days to benefit if this does hit the jackpot .
Like many folk say, if you finally hit the jackpot just once and make a million , you probably won't bother posting on LSE forums as much as you used to lol .

New slide yesterday highlighted 3 program advisors helping Faron .

Looking into their bios , they all seem to be specialists in blood cancers -

Dr Naval Daver -Dr. Naval Daver is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center.
https://mdanderson.elsevierpure.com/en/persons/naval-daver

Prof Mika Kontro - currently chairs the Finnish AML group and is a board member of the Nordic AML Group. Currently he leads a prospective multi-center AML trial VenEx utilizing ex-vivo drug sensitivity testing for individualized patient care.
https://www.helsinki.fi/en/researchgroups/individualized-therapies-acute-leukemia/people

Prof Daruka Mahadeven - At UTHSA, as Division Chief in Hematology/Medical Oncology, I will continue increase and expand the bandwidth of the early phase therapeutics portfolio to also include Investigator Initiated Studies

MD Anderson center crops up a lot in many AML and other cancer studies . Its the largest cancer center in the US .
The place to be if you want to get somewhere .

So far , Bex in Matins in US is only a one center ( UTHSA San Antonio Texas )

With one of advisors at the biggest cancer center - MD Anderson , as a prof in the Leukemia dept , you can bet your bottom dollar we will be on their list when it comes to BEXMAB site expansion .

Yes that's right and Markku was keen to highlight that in the Q&A .
Leading product.
Pole position.
Plus he said that the head & neck cohort have very low response rate to PD1 treatment , so to hit these patients with Bex , who will have a more intact immune system for it to work on , should give us the best chance . And then he said this could help steer the trial to sites that specialise in that cancer to really move it forward .

Well we've got a fair range of opinions , from old Covgas and his £1.20 , to Sir-Terz and £100
Makes old Zen look a bit cautious .
But why not £6billion ?
Bex is fast proving it can do what it says on the tin , and that will make the buyer at lot more than £6 billion through to 2037 .
I just hopes it comes in one quick sale . Not sure I could stand the decision making stress as we climbed through the £30s and £40s , then bounced around £80 before the final push .

It's a long way from previous interviews where he says the usual "discussions are ongoing" .

Its now talk of ' acquisitions , pole position , and being the leading product '

Bex is going to be taken up , no doubt .

What we may find out sooner than later is whether this gets licensed one field at a time , for example Bexmab may get snapped up by BMS perhaps , or whether someone will want the whole pie .
The universal nature of Bex ( ok not 100% proven yet , but the signals are become fairly concrete ) means that if you are a Big Pharma and you swallow up the whole program ( $2-5 billion) , you have prevented your competitors from gaining advantage .
Markku has often spoken altruistically about it being unfair to limit it to one partner , but at the end of the day , he's not going to turn down a multi $billion offer .

Bexmab may just be Farons ace card . Hence the recent re-rate I believe . people see that this could force a few hands to show their cards .